VerifAIX, an AI-native semiconductor verification startup, has raised $5 million in seed funding to scale its engineering teams and expand its chip-verification platform for fabless design houses.
TRUE ARTIS, an integrated Indian aesthetic healthcare and surgical platform, has raised Rs 11.4 crore in a seed round led by Zeropearl VC, backed by healthcare investors and operators including V3 Ventures' Arjun Vaidya, as it expands across Delhi NCR.
Jinjing Technology, also known as Goldenscope Tech, has raised RMB 300 million in Series B funding to scale production of its electron-beam lithography systems and cathodoluminescence imaging equipment used in semiconductor research.
Noetive, an AI startup building an industrial world model for factories, logistics sites and construction environments, has emerged from stealth with $41 million in seed funding led by Eclipse, backed by Meta CTO Andrew Bosworth and Airbnb CTO Ahmed Al-Dahle.
Japanese manufacturing-technology company CADDi has raised ¥17.7 billion in Series D funding, taking cumulative equity financing past ¥36 billion and valuing the company at ¥182 billion, with Toyota-backed Woven Capital and Salesforce Ventures joining as new investors.
AI biotechnology company Anew Labs has raised $290 million in its first external financing round, backed by a consortium of leading Chinese venture and growth-equity investors, at a valuation of $1.5 billion.
Bengaluru-based fashion discovery platform Slayd has closed a pre-seed funding round led by early-stage investor ajvc, adding to a wave of capital flowing into India's consumer-tech and D2C discovery layer.
September 16, 2026 emerged as one of the busiest biotech venture-financing days of the year, with Circle Pharma and Sling Therapeutics alone raising over $215 million combined, according to Fierce Biotech's 2026 fundraising tracker.
Indian startups have raised $16.3 billion across approximately 1,450 equity funding rounds so far in 2026, a 6.9% increase over the same period last year, according to Tracxn data, even as overall deal count has declined.
RegCell, an Emeryville-based biotechnology company developing therapies to restore immune tolerance, has raised $66 million in total funding, including a $44 million Series A and a non-dilutive grant from Japan's AMED.